SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

Clinical trial NCT06010953 · COMPLETED

Trial details

NCT number: NCT06010953
Sponsor: Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Male Hemophilia A With Inhibitor Hemophilia B With Inhibitor Hemophilia

Start date: 2023-10-12
Primary completion: 2024-05-07
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.